Quarterly ResultMay 11, 2026, 07:07 AM
Lexeo Therapeutics Q1 Net Loss $20.2M; LX2006 Pivotal Trial Progress
AI Summary
Lexeo Therapeutics reported a reduced net loss of $20.2 million for the first quarter of 2026, down from $32.7 million in Q1 2025, with a strong cash position of $227.6 million providing an operational runway into 2028. The company made significant progress in its clinical pipeline, submitting the LX2006 SUNRISE-FA 2 pivotal trial protocol to the FDA and anticipating initiation in Q2 2026. Interim clinical data for LX2006 showed sustained improvements in cardiac and neurologic measures, while LX2020 also demonstrated positive interim data.
Key Highlights
- Q1 2026 net loss was $20.2 million, down from $32.7 million in Q1 2025.
- Cash, cash equivalents, and investments totaled $227.6 million as of March 31, 2026.
- Company expects operational runway to extend into 2028.
- LX2006 SUNRISE-FA 2 pivotal trial protocol submitted to FDA; Q2 2026 initiation expected.
- LX2006 Phase I/II interim data showed statistically significant mFARS improvement (p=0.003).
- LX2020 HEROIC PKP2 Phase I/II trial reported positive interim clinical data.
- Laura Sepp-Lorenzino, Ph.D., appointed to the Board of Directors.